Remedy Entertainment Oyj Statistics

Total Valuation

HEL:REMEDY has a market cap or net worth of EUR 196.17 million. The enterprise value is 170.89 million.

Market Cap	196.17M
Enterprise Value	170.89M

Important Dates

The next estimated earnings date is Thursday, April 10, 2025.

Earnings Date	Apr 10, 2025
Ex-Dividend Date	n/a

Share Statistics

HEL:REMEDY has 13.59 million shares outstanding. The number of shares has increased by 0.54% in one year.

Current Share Class	n/a
Shares Outstanding	13.59M
Shares Change (YoY)	+0.54%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	39.99%
Owned by Institutions (%)	8.34%
Float	6.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	67.16
PS Ratio	3.86
PB Ratio	2.86
P/TBV Ratio	3.53
P/FCF Ratio	35.91
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 84.39, with an EV/FCF ratio of 31.28.

EV / Earnings	-47.52
EV / Sales	3.37
EV / EBITDA	84.39
EV / EBIT	n/a
EV / FCF	31.28

Financial Position

The company has a current ratio of 2.90, with a Debt / Equity ratio of 0.23.

Current Ratio	2.90
Quick Ratio	2.90
Debt / Equity	0.23
Debt / EBITDA	7.82
Debt / FCF	2.90
Interest Coverage	-13.25

Financial Efficiency

Return on equity (ROE) is -5.28% and return on invested capital (ROIC) is -3.43%.

Return on Equity (ROE)	-5.28%
Return on Assets (ROA)	-2.99%
Return on Invested Capital (ROIC)	-3.43%
Return on Capital Employed (ROCE)	-5.16%
Revenue Per Employee	138,041
Profits Per Employee	-9,798
Employee Count	367
Asset Turnover	0.57
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -12.00% in the last 52 weeks. The beta is 0.54, so HEL:REMEDY's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	-12.00%
50-Day Moving Average	13.67
200-Day Moving Average	15.38
Relative Strength Index (RSI)	59.28
Average Volume (20 Days)	6,221

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HEL:REMEDY had revenue of EUR 50.66 million and -3.60 million in losses. Loss per share was -0.27.

Revenue	50.66M
Gross Profit	34.10M
Operating Income	-4.28M
Pretax Income	-3.82M
Net Income	-3.60M
EBITDA	646,000
EBIT	-4.28M
Loss Per Share	-0.27

Full Income Statement

Balance Sheet

The company has 41.11 million in cash and 15.83 million in debt, giving a net cash position of 25.28 million or 1.86 per share.

Cash & Cash Equivalents	41.11M
Total Debt	15.83M
Net Cash	25.28M
Net Cash Per Share	1.86
Equity (Book Value)	68.53M
Book Value Per Share	5.05
Working Capital	31.00M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 12.27 million and capital expenditures -6.81 million, giving a free cash flow of 5.46 million.

Operating Cash Flow	12.27M
Capital Expenditures	-6.81M
Free Cash Flow	5.46M
FCF Per Share	0.40

Full Cash Flow Statement

Margins

Gross margin is 67.32%, with operating and profit margins of -8.45% and -7.10%.

Gross Margin	67.32%
Operating Margin	-8.45%
Pretax Margin	-7.54%
Profit Margin	-7.10%
EBITDA Margin	1.28%
EBIT Margin	-8.45%
FCF Margin	10.78%

Dividends & Yields

HEL:REMEDY does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.54%
Shareholder Yield	-0.54%
Earnings Yield	-1.83%
FCF Yield	2.78%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HEL:REMEDY has an Altman Z-Score of 5.52.

Altman Z-Score	5.52
Piotroski F-Score	n/a